Program Chair – 23rd Clinical & Pharmaceutical Solutions through Analysis USA (CPSA USA 2020)
Melanie Anderson, Merck
“What I love about CPSA is that it continues to ask the questions, what are we trying to do? And where is it that we are trying to go?”- Melanie Anderson, Merck
“Why are we taking 6 mL when we can take 100 µL?” – Melanie Anderson, Merck
With the pandemic, the design and execution of clinical trials has become more challenging. Melanie asks the questions – “What are the ways that we can make a patient’s life better?”, “What would be a better treatment?” and “What can we do differently?” Healthcare has fundamentally changed in the face of the pandemic, creating new challenges and opportunities for patients in clinical trials and their treatments. Melanie puts forth a discussion on engaging patients to understand their needs – while building capabilities like telemedicine and at home microsampling. We can work together to help change parts of a larger healthcare system, ultimately serving to improve patient care.